IMUGENE LIMITED — Board/Management Information 2023

Mar 1, 2023

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Imugene appoints CFO Mike Tonroe as Company Secretary

Sydney, Australia, 2 March 2023: Imugene Limited (ASX:IMU), a clinical stage immunooncology company, is pleased to announce the appointment of Chief Financial Officer (CFO) Mike Tonroe as Company Secretary, effective 2 March 2023.

Mr Tonroe commenced as CFO of Imugene in September 2022. In addition to being an experienced CFO, Mr Tonroe was previously Company Secretary of ASX and NASDAQlisted Genetic Technologies Limited and Opthea Limited.

Phillip Hains and Nathan Jong will step down as Company Secretaries effective 2 March 2023.

Imugene’s M.D. & CEO, Ms Leslie Chong said: "We are pleased to expand Mr. Tonroe’s role to include that of Company Secretary. With Imugene's growth, it is appropriate to now bring the role of company secretary in-house, and I would like to thank Phillip Hains of The CFO Solution for his valuable contribution as Company Secretary since 2012."

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

Connect with us on LinkedIn @Imugene Limited View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

IMUGENE LIMITED ACN 009 179 551

2